Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SYK 
Stryker Corporation (SYK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: SYK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $421.46
1 Year Target Price $421.46
| 13 | Strong Buy |
| 9 | Buy |
| 9 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.85% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 148.84B USD | Price to earnings Ratio 52.63 | 1Y Target Price 421.46 |
Price to earnings Ratio 52.63 | 1Y Target Price 421.46 | ||
Volume (30-day avg) 32 | Beta 0.93 | 52 Weeks Range 312.11 - 404.39 | Updated Date 07/12/2025 |
52 Weeks Range 312.11 - 404.39 | Updated Date 07/12/2025 | ||
Dividends yield (FY) 0.85% | Basic EPS (TTM) 7.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.31% | Operating Margin (TTM) 19.3% |
Management Effectiveness
Return on Assets (TTM) 7.49% | Return on Equity (TTM) 14.26% |
Valuation
Trailing PE 52.63 | Forward PE 29.33 | Enterprise Value 163209928322 | Price to Sales(TTM) 6.41 |
Enterprise Value 163209928322 | Price to Sales(TTM) 6.41 | ||
Enterprise Value to Revenue 7.03 | Enterprise Value to EBITDA 29.02 | Shares Outstanding 382164992 | Shares Floating 344265575 |
Shares Outstanding 382164992 | Shares Floating 344265575 | ||
Percent Insiders 5.37 | Percent Institutions 81.04 |
Upturn AI SWOT
Stryker Corporation
Company Overview
History and Background
Stryker Corporation was founded in 1941 by Dr. Homer Stryker, an orthopedic surgeon. Initially focusing on medical beds and orthopedic devices, it has grown through innovation and acquisitions to become a leading medical technology company.
Core Business Areas
- MedSurg: This segment includes surgical equipment and surgical navigation systems, endoscopic and communications equipment, patient handling and emergency medical equipment, as well as reprocessed and remanufactured medical devices.
- Orthopaedics and Spine: This segment focuses on implants used in hip, knee, and shoulder joint replacements, as well as trauma and extremity surgeries. It also includes spinal implants.
- Neurotechnology and Spine: This segment offers products for neurosurgery, stroke intervention, and spine procedures.
Leadership and Structure
Kevin A. Lobo serves as the Chairman and Chief Executive Officer. Stryker operates with a decentralized structure, empowering individual business units while maintaining central oversight.
Top Products and Market Share
Key Offerings
- Mako Robotic-Arm Assisted Surgery System: This robotic arm assists surgeons in performing knee and hip replacements with greater precision. Stryker holds a significant market share in robotic surgery. Competitors include Smith+Nephew (SNN), Zimmer Biomet (ZBH) and Medtronic (MDT).
- Trauma and Extremities: Implants and devices used in orthopedic trauma surgeries. Stryker's market share in this area is substantial. Competitors include DePuy Synthes (Johnson & Johnson - JNJ) and Smith+Nephew (SNN).
- Neurovascular Products: Devices for stroke intervention and neurosurgical procedures, showing strong growth potential. Competitors include Medtronic (MDT) and Penumbra (PEN).
Market Dynamics
Industry Overview
The medical technology industry is experiencing growth driven by an aging population, increasing demand for minimally invasive procedures, and technological advancements.
Positioning
Stryker is a leading player in the medical technology industry, known for innovation, a broad product portfolio, and strong brand recognition. Its competitive advantage lies in its robotic surgery platform and diversified business segments.
Total Addressable Market (TAM)
The global medical technology market is estimated to be worth hundreds of billions of dollars, with projections for continued growth. Stryker is well-positioned to capture a significant share of this expanding market.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified product portfolio
- Innovative robotic surgery platform
- Global presence
- Strong financial performance
Weaknesses
- High reliance on acquisitions for growth
- Pricing pressure in some segments
- Exposure to regulatory risks
- Dependence on hospital capital spending
- Complexity of product portfolio management
Opportunities
- Expanding into emerging markets
- Developing new robotic surgery applications
- Leveraging data analytics and AI
- Acquiring complementary technologies
- Increasing adoption of minimally invasive procedures
Threats
- Increasing competition
- Healthcare cost containment pressures
- Product liability claims
- Disruptive technologies
- Economic downturns affecting hospital budgets
Competitors and Market Share
Key Competitors
- ZBH
- JNJ
- BSX
- MDT
- SNN
Competitive Landscape
Stryker's advantages include its robotic surgery platform, diversified portfolio, and global reach. Its disadvantages include pricing pressure and reliance on hospital capital spending. Competitors are aggressively innovating and expanding their product portfolios.
Major Acquisitions
Vocera Communications
- Year: 2022
- Acquisition Price (USD millions): 3090
- Strategic Rationale: Acquisition expanded Stryker's digital healthcare offerings by adding Vocera's communication and workflow solutions to enhance the continuum of care.
Growth Trajectory and Initiatives
Historical Growth: Stryker has achieved consistent revenue and earnings growth through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued revenue growth driven by demand for Stryker's products and services. Earnings growth is expected to outpace revenue growth due to operating leverage.
Recent Initiatives: Recent initiatives include investments in R&D, expansion into new markets, and the launch of new products such as advanced surgical navigation systems.
Summary
Stryker is a strong medical technology company with a diversified portfolio and a leading position in robotic surgery. Its growth is fueled by innovation and strategic acquisitions. The company faces challenges from competition and healthcare cost pressures, but is well-positioned for long-term success. Stryker needs to monitor the acquisitions for synergies and new product roll-outs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Investor Relations
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stryker Corporation
Exchange NYSE | Headquaters Portage, MI, United States | ||
IPO Launch date 1988-02-01 | Chairman, CEO & President Mr. Kevin A. Lobo | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.stryker.com |
Full time employees 53000 | Website https://www.stryker.com | ||
Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.